Vitamin D Deficiency Is Associated With Low Mood and Worse Cognitive

Performance in Older Adults

Consuelo H. Wilkins, M.D., Yvette I. Sheline, M.D.,Catherine M. Roe, Ph.D., Stanley J. Birge, M.D.,John C. Morris, M.D.

Background: Vitamin D deficiency is common in older adults and has been impli-
cated in psychiatric and neurologic disorders. This study examined the relationship
among vitamin D status, cognitive performance, mood, and physical performance in
older adults.
Methods:  A cross-sectional group of 80 participants, 40 with mild
Alzheimer disease (AD) and 40 nondemented persons, were selected from a longitu-
dinal study of memory and aging. Cognitive function was assessed using the Short
Blessed Test (SBT), Mini-Mental State Exam (MMSE), Clinical Dementia Rating (CDR;
a higher Sum of Boxes score indicates greater dementia severity), and a factor score
from a neuropsychometric battery; mood was assessed using clinician’s diagnosis
and the depression symptoms inventory. The Physical Performance Test (PPT) was
used to measure functional status. Serum 25-hydroxyvitamin D levels were measured
for all participants.
Results: The mean vitamin D level in the total sample was 18.58
ng/mL (standard deviation: 7.59); 58% of the participants had abnormally low
vitamin D levels defined as less than 20 ng/mL. After adjusting for age, race, gender,
and season of vitamin D determination, vitamin D deficiency was associated with
presence of an active mood disorder (odds ratio: 11.69, 95% confidence interval:
2.04–66.86; Wald 2 7.66, df2, p0.022). Using the same covariates in a linear
regression model, vitamin D deficiency was associated with worse performance on
the SBT (F5.22, df[2, 77], p 0.044) and higher CDR Sum of Box scores (F3.20,
df[2, 77], p0.047) in the vitamin D-deficient group. There was no difference in
performance on the MMSE, PPT, or factor scores between the vitamin D groups.
Conclusions: In a cross-section of older adults, vitamin D deficiency was associated
with low mood and with impairment on two of four measures of cognitive perfor-
mance. (Am J Geriatr Psychiatry 2006; 14:1032–1040)
Key Words: Vitamin D, mood disorder, cognitive impairment

Vitamin D and Mental Illness von John Jacob Cannell MD
Aus dem Amerikanischen - ein engagierter forschernder Arzt

ABSTRACT

We propose vitamin D plays a role in mental illness based on the following five reasons: Epidemiological evidence shows an association between reduced sun exposure and mental illness. Mental illness is associated with low 25-hydroxyvitamin D [25(OH)D] levels. Mental illness shows a significant comorbidity with illnesses thought to be associated with vitamin D deficiency. Theoretical models (in vitro or animal evidence) exist to explain how vitamin D deficiency may play a causative role in mental illness. Studies indicate vitamin D improves mental illness.

First, we review recent evidence concerning the hitherto unexpectedly high human requirements for vitamin D. Then, we briefly review the physiology, toxicology, and evidence for widespread vitamin D deficiency.

After that we review epidemiological evidence that mental illness has increased as humans have migrated out of the sun followed by additional epidemiological evidence that associates vitamin D deficiency with mental illness. Studies associating season of birth with mental illness are briefly reviewed. Two small reports studied the association of low 25(OH) D levels with mental illness and both were positive.

Depression has significant co-morbidity with illnesses associated with hypovitaminosis D such as osteoporosis, diabetes, heart disease, hypertension, multiple sclerosis, and rheumatoid arthritis. Schizophrenia is associated with cardiac disease , diabetes (before the introduction of the atypical antipsychotics) , osteoporosis , and hypertension  —but not multiple sclerosis.

Vitamin D has a significant biochemistry in the brain. Nuclear receptors for vitamin D exist in the brain and vitamin D is involved in the biosynthesis of neurotrophic factors, synthesis of nitric oxide synthase, and increased glutathione levels—all suggesting an important role for vitamin D in brain function. Animal data indicates that tyrosine hydroxylase, the rate-limiting enzyme for all the brain's monoamines, is increased by vitamin D. Rats born to severely vitamin D deficient dams have profound brain abnormalities.

We found only three small studies in which vitamin D was given to improve mood, but two found a positive effect. The negative study used homeopathic doses (low doses) of vitamin D2 ergocalciferol.

Finally we briefly review toxicity and suggest treatment. Fear of vitamin D toxicity is unwarranted but rampant in the medical profession. Because vitamin D deficiencies are so widespread in the western world, psychiatrists should suspect the deficiency—especially in blacks, the aged, and those who avoid the sun. Serum 25(OH)D levels should be obtained when deficiency is suspected. Judicial exposure to sunlight, oral vitamin D, or both, aimed at restoring circulating levels of25(OH)D to between 50–80 ng/mL, is the treatment of choice for vitamin D deficiency in mentally ill patients. Cholecalciferol is the preferred oral preparation of vitamin D.HUMAN REQUIREMENTS FOR VITAMIN D

For otherwise healthy persons, the FNBreports adequate intake (AI) for vitamin D is 200, 400, or 600 IU a day, depending on your age.  Dr. Robert Heaney, et al, writing in theAmerican Journal of Clinical Nutrition in 2003 said: "The recommendations of the Food and Nutrition Board with respect to oral vitamin D input fall into a curious zone between irrelevance and inadequacy. For those persons with extensive solar exposure, the recommended inputs add little to their usual daily production, and for those with no exposure, the recommended doses are insufficient to ensure desired 25(OH)Dconcentration."

It now appears that physiological human requirements for vitamin D (from all sources) are approximately 10 times higher than the current AI listed by the 1997 Food and Nutrition Board (FNB).    

An AI is a crude estimate of the amount theFNB thought necessary to prevent vitamin D deficient diseases such as osteomalacia (softening of the bones) and rickets in 95% of the at-risk population. It is not a recommended intake. The FNB also reports that the upper limit (UL) of vitamin D is 2,000 IU/day. The FNB defines UL as, the highest daily level of chronic nutrient intake that is likely to pose no risk of adverse health effects to almost all individuals in the general population.  Thus the definition of UL implies some risk to vulnerable members of the population who exceed the UL.

The problem with the FNB's recommendation is that most of us greatly exceed the UL of vitamin D by simply spending a few minutes outside in our bathing suits.  The authors could find nothing in the medical literature that contradicts Dr. Michael Holick's 1995 demonstration that a brief dose of noontime summer sun is comparable to taking between 10,000–25,000 IU of vitamin D. Four earlier papers all found similar amounts of natural vitamin D production. Adam, et al found that up to 50,000 IU of vitamin D was released into the circulation of Caucasians after 30 minutes of noontime summer sun.  Three additional studies support the fact that at least 8,000–10,000 IU/day are routinely made in human skin following brief exposure to UVB.   Physiological Amounts

Holick now believes that a full body minimal erythemal dose of summer sunlight at noontime produces 20,000 IU of vitamin D. The high amount of natural human production of vitamin D is the single most important fact every physician should know about vitamin D because it has such profound implications for the natural human condition. Furthermore, there has never been a reported case of vitamin D intoxication due to excessive sun-exposure such as lifeguards, sun-worshippers, etc. The reason is that once the skin makes enough vitamin D, the sun destroys the excess.
These amounts are, by definition, physiological. The skin makes them after relatively brief period in the sun—at least in Caucasians in the summer, at temperate latitudes, and as long as clothes, glass, or sunblock do not cover the skin. It is important to note that blacks need 5–10 times longer in the sun than do whites to achieve similar vitamin D production.

Such seemingly high rate of vitamin D production leads us to, an overwhelming question...Why did nature do this? Cholecalciferol is a prehormone

Although vitamin D is said to be a vitamin, significant amounts of vitamin D are not found in the foods humans naturally consume. A hundred years ago, after we were steadily migrating out of the sun and into buildings, cars, and layers of sun block, Northern Europeans realized that adding a teaspoon of fish oil to infants' diets helped them thrive. How did we decide how much to add? We guessed based on animal models of rickets. Correctly, it turned out, to prevent rickets in children. But the same dose was applied to adults, and therefore the adult dose was off by a factor of 10. This mistake continues to this day.

Cholecalciferol, the naturally occurring form of vitamin D, is a prehormone made in the skin by the action of sunlight on 7-dehydrocholesterol (also known as provitamin D3). As this is meant to be a clinical paper, we will not detail the physiology and biochemistry of vitamin D. For excellent clinical reviews that give more details of vitamin D physiology, see Holick , Zittermann , and Vieth.

For our purposes, suffice it to say that nature designed a system in which humans go in the sun, make thousands of units of cholecalciferol which the liver then hydroxylates into 25-hydroxyvitamin D, or 25(OH)D. Our organs then make a steroid hormone, 1,25-dihydroxyvitamin D, which has both endocrine and paracrine functions. Although the endocrine function of 1,25(OH)2D3 made in the kidney is well known, the paracrine function is a relatively new discovery and appears to occur in every organ in the body.

1,25(OH)2D3 helps regulate gene expression in more than 30 tissues and the list keeps growing. More succinctly, humans have a vitamin D system which makes thousands of units of the prehormone 25(OH)D within hours of sun exposure so various organs can then make the steroid hormone 1,25(OH)2D3 to help regulate genes in apparently every organ in the body.  We assume nature created this system for a good reason.5,000 IU Per Day
Support for the growing realization that well adults and adolescents need a minimum of 5,000 IU of vitamin D a day (from all sources, diet, sun and supplements) includes:Recent studies by Heaney, et al conclude healthy men utilize between 3,000–5,000 IU of cholecalciferol a day, mostly from stores made by the summer sun. Humans living near the equator, where we evolved, have mean serum 25(OH)D levels of more than 40 ng/mL, levels requiring solar input of about 4,000 IU of vitamin D a day. American lifeguards, working in swimsuits, have even higher 25(OH)D levels, at 64 ng/mL, in spite of temperate latitudes. In 2003, Gomez recently produced evidence that excessive secretion of the parathyroid gland, known as secondary hyperparathyroidism, is almost nonexistent when 25(OH)D levels exceed 30 ng/mL(requiring 3,000 IU/day).  Dr. Vieth cited six studies that concluded, if the aim is to keep parathyroid hormone concentrations low,25(OH)D levels should exceed 28 ng/mL(70 nmol/L). Heaney and his colleagues recently showed that calcium absorption increases as 25(OH)D blood levels increase.  With blood levels of 34 ng/mL (equivalent to about 3,000  IU/day total intake), calcium absorption was 65% higher than when levels are 20 ng/mL. This implies that part of the reason humans need to take so much extra calcium is because there is widespread deficiency of vitamin D. when speaking of 25(OH)D blood levels, the authors were blunt, "We conclude that the lower end of the current reference range is set too low." Blood pressure is reduced significantly by ultraviolet radiation comparable to about oral intake of 3,000 IU of vitamin D a day,  but blood pressure is not routinely reduced by small amounts of vitamin D. Daily doses of 2,500 IU of vitamin D helped rheumatoid arthritis  but small amounts did not. Infants receiving 2,000 IU a vitamin D a day were almost fully protected (relative risk 0.12) from developing type 1 diabetes 30 years later.5,000 IU of vitamin D a day, along with calcium and magnesium, decreased the relapse rate in multiple sclerosis patients. Multiple sclerosis is rare around the equator. To our knowledge, all studies of vitamin D and fractures demonstrate reduced fracture rates, as long as 25(OH)D levels increased to more than 40 ng/mL after treatment.  Breast milk (nature's perfect food) is deficient in vitamin D. Does this mean Paleolithic humans were supposed to expose their young to the sun (and thus to predators)? Dr. Bruce Hollis recently discovered that breast-feeding mothers need 4,000 units of vitamin D a day to sustain themselves and their infant. 2,000 units a day was not effective. It seems likely to the authors that the lack of vitamin D in human breast milk is due to widespread deficiency in mothers. Humans make thousands of units of vitamin D within minutes of whole body exposure to sunlight. From what we know of nature, it is unlikely such a system evolved by chance. Deficiency Common In Older Adults

Vitamin D deficiency is common in older adults, even using conservative cutoff levels for25(OH)D at <15 ng/mL, with a reported prevalence of 57% of medical inpatients. Thomas found that those patients with deficiencies were more likely to have nephrotic syndrome, hypertension and diabetes as well as higher parathyroid hormone concentrations.
14% of 1569 otherwise healthy urban French adults had Vitamin D deficiency, with 25(OH)D levels lower than 12 ng/mL.  63% of 60 neonates had 25(OH)D levels less than 12 ng/mL and 14 of those 60 infants had serumPTH concentrations of more than 60 ng/mL. In Canada, more than 20% of healthy young women have low 25(OH)D levels at less than 16 ng/mL and the prevalence was higher among non-whites, as expected due to skin pigmentation.  Vieth clearly pointed out that vitamin D supplements (such as multivitamins or dairy products) did not prevent the deficiency—in fact the two were not even related. Fuller and Casparian, in 2001, reviewed the literature and concluded, "Previous studies that have found serum levels of vitamin D in their sun-protected subjects to be in the normal range may need to be reevaluated."  42% of African American women had hypovitaminosis D (25(OH)D<15 ng/mL) as compared to only 4.2% of whites.  As early as 1992, other authors found a significant incidence of hypovitaminosis D. REDUCED SUN EXPOSURE

Epidemiological evidence suggests that mental illness has increased as humans have migrated out of the sun and into buildings, cars, and sunblock. In a meticulously researched 2002 monograph, E. Fuller Torrey systematically compiled statistics on the incidence of "insanity" from every conceivable source covering the last 250 years.  His work indicated a dramatic increase in insanity (schizophrenia and severe bipolar disorder), that he labeled "The Invisible Plague." Although severe methodological limitations apply to any such endeavor, Torrey makes a convincing argument that the current incidence of insanity is not part of the human condition and has increased more than 20 fold in the last 250 years.

Torrey's work follows the classic 1989 paper by Klerman and Weissman which documented very significant temporal increases in the rates of major depression in cohorts born after World War II, including a decrease in the age of onset.  The authors reviewed all available studies relevant to temporal trends in depression and concluded that dramatic increases were occurring in a relatively short time, much as Torrey would claim 12 years later. For example, Klerman and Weissman claimed that those born before 1915 had less than a 10% lifetime risk of developing a diagnosable major affective disorder while their relative cohorts born after 1955 had a 40% chance. Such dramatic increases in the rates of depression are known in psychiatry as the "Cohort Effect." The existence of such an effect has been heavily debated since Klerman and Weissman's original publication with other authors contending that recall bias or methods effects may explain these findings.  

The implications for such an epidemic or cohort effect are staggering. A recent Consensus Development Conference on geriatric mental illness reported that the number of people older than 65 years with psychiatric disorders in the United States will increase from about 4 million in 1970 to 15 million in 2030, a 275% increase.

Although the cohort effect in depression shows dramatic increases, supporting Torrey's contention of a "Silent Epidemic," trends in schizophrenia over the last 50 years are less clear.  There is evidence that measures of long-term trends in perinatal sunshine duration are associated with epidemiological features of schizophrenia.  In 1997, Torrey, et al, reviewed more than 250 studies concluding they are "remarkably consistent in showing a 5–8% winter-spring excess of births for both schizophrenia and mania/bipolar disorder." The same authors concluded a seasonal factor was also evident in schizoaffective disorder, major depression, and autism.
Castrogiovanni, et al, also concluded a 10% birth excess during winter for schizophrenia with fewer studies supporting similar effects for bipolar disorder and major depressive disorder. Cassidy and Carroll reviewed the seasonal pattern of 304 psychiatric admissions for bipolar/mania and concluded manic hospitalizations peaked in early spring and reached a nadir in late fall.  In Singapore, where UVB and vitamin D production remains constant year-round, seasonal excess of schizophrenia birth rates was not evident in 9,655 patients, providing further evidence supporting a sunlight effect in schizophrenic births.

McGrath has long contended that widespread vitamin D deficiency leads to low prenatal vitamin D levels which, in turn, contribute to various adult disorders, including schizophrenia via "imprinting."   He cites duration of sunshine, higher latitude, worse outcome at higher latitude, increased incidence in dark-skinned migrants to northern latitudes, urban birth, and season of birth as all being risk factors for schizophrenia and all consistent with a vitamin D effect. Kendell and Adams were recently unable to support the hypothesis that vitamin D deficiency in pregnancy or early infancy may contribute to schizophrenia. LOW 25(OH)D LEVELS

25(OH)D levels of 31 patients with schizophrenia and 25 with depression were compared to 30 alcoholics and 31 healthy controls. Mean 25(OH)D levels (in pg/mL) were lower in the depression (37.3) group and significantly lower in the schizophrenia (35.1) groups compared to normal controls (45.9). More recently, sera from third trimester pregnant black women showed low maternal vitamin D might be a risk factor for schizophrenia among blacks, but the association didn't hold for white women. VITAMIN D DEFICIENCY DISEASES

Mental illness is associated with most of the other illnesses that have been associated with vitamin D deficiency.   For example, depression is associated with increased mortality, especially cardiac mortality.  Recent studies have demonstrated that depression is a major risk for type 2 diabetes. Type 1 diabetes appears to have similar associations.  Poor quality of life was associated with high diastolic blood pressure among women.
Michelson, et al, found past or current depression is associated with decreased bone mineral density in women.  However, Amsterdam and Hooper observed no difference in mean BMD values between depressed patients and controls.  The Cardiovascular Health Study found significant associations between bone mineral density and depression after adjusting for osteoporosis risk factors.  The authors postulated, "there may be an unmeasured third factor, such as an endogenous steroid, that is responsible for both low BMD and depression," without mentioning that vitamin D is a steroid.

Patients with multiple sclerosis often have comorbid depressions.   Rheumatoid arthritis patients, especially urban residents, have more depression than osteoarthritis patients do—a difference not explained by disease severity or duration.

Schizophrenia has been reported to be comorbid with cardiac disease, diabetes, and osteoporosis.  The increased rate of diabetes in schizophrenics was recognized before the atypical antipsychotics were introduced. Schizophrenia also appears to be associated with hypertension. VITAMIN D AND BRAIN FUNCTION

In 2002 Garcion, et al, reviewed clues about vitamin D function in the brain. They concluded1,25(OH)2D3 is involved in brain function with nuclear receptors for vitamin D localized in neurons and glial cells. Genes encoding the enzymes involved in the metabolism of this hormone (1,25(OH)2D3) are also expressed in brain cells. The reported biological effects of1,25(OH)2D3 in the nervous system include the biosynthesis of neurotrophic factors and at least one enzyme involved in neurotransmitter synthesis. 1,25(OH)2D3 can also inhibit the synthesis of inducible nitric oxide synthase and increase glutathione levels, suggesting a role for the hormone in brain detoxification pathways. Neuroprotective and immunomodulatory effects of this hormone have been described in several experimental models, indicating the potential value of pharmacological analogs in neurodegenerative and neuroimmune diseases. In addition,1,25(OH)2D3 induces glioma cell death, making the hormone of potential interest in the management of brain tumors.

Tyrosine hydroxylase is the rate-limiting enzyme for production of the brain's monoamines. Vitamin D increases expression of the tyrosine hydroxylase gene in adrenal medullary cells of mice.  Such a mechanism has been hypothesized to increase brain serotonin levels.  Deficits of specificGABAergic neurons—defined by the presence of calcium-binding proteins parvalbumin, calbindin, and calretinin—are present in schizophrenia.
POSITIVE EFFECT

Vitamin D3 (400 and 800 IU) significantly enhanced positive affect when given to 44 healthy individuals.  100,000 IU of ergocalciferol improved depression scales better than light therapy in a small group of patients with seasonal affective disorder.  In the later study, improvement in 25(OH)D levels was significantly associated with improvement in depression scale scores.

400 IU of ergocalciferol did not effect mood scores in 125 Boston women compared to placebo. 25(OH)D levels were not drawn but we now know 400 IU of ergocalciferol is a homeopathic dose.

The authors were unable to find any studies in the literature in which mentally ill patients were treated with physiological doses of vitamin D.


TOXICITY

Vieth attempted to dispel fears in the medical community about physiological doses of vitamin D in 1999 with his exhaustive and well-written review.  His conclusions: fear of vitamin D toxicity is unwarranted, and such unwarranted fear is rampant in the medical profession.  Even Ian Monroe, the chair of the relevant IOM committee, wrote to the Journal to compliment Vieth's work and to promise his findings will be considered at the time of a future Institute of Medicine review.  That was more than 2 years ago.

Vieth indirectly asked the medical community to produce any evidence 10,000 units of vitamin D a day was toxic, saying, "Throughout my preparation of this review, I was amazed at the lack of evidence supporting statements about the toxicity of moderate doses of vitamin D." He added, "If there is published evidence of toxicity in adults from an intake of 250 µg(10,000 IU) per day, and that is verified by the25(OH)D concentration, I have yet to find it."

It is true that a few people may have problems with high calcium due to undiagnosed vitamin D hypersensitivity syndromes such as primary hyperparathyroidism, granulomatous disease (mainly sarcoidosis), or some cancers. This is not vitamin D toxicity and such syndromes often occur in patients with relative vitamin D deficiencies.

Cholecalciferol is certainly toxic in excess, and is used a rodent poison for this purpose. Animal data indicates signs of toxicity can occur with ingestion of 0.5 mg/kg(20,000 IU/kg), while the oral LD50 for cholecalciferol in dogs is about 88 mg/kg(3,520,000 IU/kg).  This would be equivalent to a 50 kg adult taking 176,000,000 IU or 440,000 standard 400 IU cholecalciferol capsules. Vieth reports human toxicity begins to occur after chronic consumption of approximately 40,000 IU a day.

One could compare vitamin D toxicity to water intoxication. For example, 8 glasses of water a day is recommended consumption. However, regular consumption of 80 glasses a day (as seen in compulsive water intoxication) can be fatal. So you could say that water has a therapeutic index of 10 (80/8).

Most vitamin D experts now say that humans should get about 4,000 units of vitamin D a day (from all sources), but 40,000 units a day will hurt them (over several years).  Therefore, vitamin D has a therapeutic index of 10 (40,000/4,000), the same as water. Although we are not saying it is as safe as water, we are saying vitamin D is safe when used in the doses nature uses it.

The single most important fact anyone needs to know about vitamin D is how much nature supplies if we behave naturally, e.g., go into the sun. Whites make about 20,000 units of vitamin D within 30 minutes of full body exposure to the sun (minimal erythemal dose). Vitamin D production in the skin occurs within minutes and is already maximized before your skin turns pink. Furthermore, if one stays in the sun long enough, the sun starts destroying excess vitamin D, a natural safeguard against toxicity.

Fear of the fatal form of skin cancer, malignant melanoma, keeps many people out of the sun. The problem with the theory is that the incidence of melanoma continues to increase dramatically although many people have been completely avoiding the sun for years.  We are not saying sunburns are safe, they are not. We are saying that brief full body sun exposure (one-third minimal erythemal doses) may slightly increase your risk of non-melanoma skin cancer, but it is a much smarter thing to do than suffering from vitamin D deficiency.

Although there are documented cases of pharmacological overdoses from ergocalciferol, the only documented case of pharmacological (not industrial) toxicity from cholecalciferol we could find was intoxication from an over-the-counter supplement called Prolongevity. On closer inspection, however, it seemed more like an industrial accident but is interesting because it gives us some idea of the safety of cholecalciferol. The powder consumed contained up to 430 times the amount of cholecalciferol contained on the label (2,000 IU). The man had been taking between 156,000–2,604,000 IU of cholecalciferol (equivalent to between 390–6510 of the 400 IUcapsules) a day for 2 years. He recovered uneventfully after treatment with glucocorticoids and sunscreen.


VITAMIN D AS TREATMENT

It is too early to say that repletion of the vitamin D system will improve psychiatric symptoms, but there is limited evidence that it may. Once vitamin D deficiency is diagnosed in a psychiatric patient, or any patient, the physician needs to replete the vitamin D system with sunlight, an artificial source ofUVB, oral vitamin D3, or a combination of the three alternatives. Regardless of the method used, the physician should be sure 25(OH)Dlevels are maintained between 50–80 ng/mL.

In Caucasian patients who want to avoid taking medication, judiciously exposing of as much skin as possible to direct midday sunlight for a few minutes (time needed depends on skin type) 3 times a week during those months when UVB occurs at their latitude (The Holick method) will maintain vitamin D levels.

Black patients will need 5–10 times longer in the sun. After several months of sun exposure, a 25(OH)D level should be obtained again to ensure levels between 50–80 ng/mL. Artificial light sources are available which emit UVB and which have been shown to increase serum25(OH)D levels.

For those who want to avoid the sun or artificial light sources, cholecalciferol is the preferred form of vitamin D. It is the compound your skin makes naturally when exposed to UVB. It is more potent and is safer than the synthetic analog, ergocalciferol, in more common use. Cholecalciferol is 1.7 times more efficient at raising 25(OH)D levels than is ergocalciferol. If oral cholecalciferol is the only source of vitamin D (complete lack of UVB exposure), at least 5,000 IU per day will be needed to ensure serum 25(OH)D levels in the desirable range.

Unfortunately, when doctors don't prescribe ergocalciferol, they sometimes prescribe newer vitamin D analogs, costing thousands of times more than cholecalciferol. Vitamin D analogs are contraindicated in vitamin D deficiency because they may cause hypercalcemia and fail to address the real problem: low stores of25(OH)D. Cholecalciferol, or ergocalciferol, will replete the vitamin D system by filling up your gas tank with vitamin D.  Giving newer, synthetic 1,25 vitamin D analogs for vitamin D deficiency is like shooting ether into your engine to keep your car running.

There is reason to hope that treating vitamin D deficiency will help improve the lives of psychiatric patients. It also seems clear that restoring physiological serum levels of25(OH)D will hurt very few, if any, patients.

John Jacob Cannell MD Executive Director 2003.09.07 updated 2010.01.08